<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135327</url>
  </required_header>
  <id_info>
    <org_study_id>20070492</org_study_id>
    <nct_id>NCT03135327</nct_id>
  </id_info>
  <brief_title>Clinical Applications of Advanced Ophthalmic Imaging</brief_title>
  <official_title>Clinical Applications of Advanced Ophthalmic Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical application of advanced ophthalmic&#xD;
      imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI),&#xD;
      slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls.&#xD;
&#xD;
      There are two phases in this study. The first phase is an observational phase which studies&#xD;
      the eye in various conditions. The second phase is an interventional phase which studies the&#xD;
      changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2007</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal microstructure using OCT.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Optical coherence tomography is used to measure the thickness of intraretinal layers. The measurement is in micrometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal vasculature by optical coherence tomography angiography (OCTA)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Retinal vascular network density in percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival vasculature by functional slit-lamp (FSLB)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Conjunctival vascular network density in percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal epithelial thickness</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Measured in micrometers using ultra high resolution OCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear film thickness</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Measured in micrometers using ultra high resolution OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal blood flow velocity by retinal function imager (RFI)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Retinal blood flow velocity in mm/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival blood flow velocity by functional slit-lamp (FSLB)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Conjunctival blood flow velocity in mm/s</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Dry Eye Syndromes</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Presbyopia</condition>
  <condition>Myopia</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Interventional Phase - Ocufolin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive the Ocufolin medical food for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Phase Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this group will be studied and followed up for 1-2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ocufolin</intervention_name>
    <description>Ocufolin medical food capsules will be taken once a day by mouth each morning with a meal for the first week, two capsules orally each morning with a meal for the second week and three capsules orally each morning with a meal for the rest of the 6 months study duration.</description>
    <arm_group_label>Interventional Phase - Ocufolin Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Observational Phase 1 Group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Self-reported normal healthy subjects;&#xD;
&#xD;
          2. Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple&#xD;
             sclerosis, dry eye, myopia, diabetics and stroke;&#xD;
&#xD;
          3. Who can keep the eye open for imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. who can not read and sign the ICF;&#xD;
&#xD;
          2. who can not receiving ophthalmic imaging;&#xD;
&#xD;
          3. who cannot tolerate bright light during imaging.&#xD;
&#xD;
        Interventional Phase 2 Group:&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
        The participant will be eligible for entry in the study if s/he:&#xD;
&#xD;
          1. Is at least 18 years old and has full legal capacity to volunteer;&#xD;
&#xD;
          2. Has read and signed the IRB Informed Consent Document;&#xD;
&#xD;
          3. Is willing and able to follow participant instructions;&#xD;
&#xD;
          4. Has clear corneas and crystalline lens;&#xD;
&#xD;
          5. Initial visual acuities were 20/80 or better;&#xD;
&#xD;
          6. MTHFR C677TT homozygous, or MTHFR C677T/A1298C compound heterozygous with mild to&#xD;
             moderate micro-aneurismal vascular retinopathy disease;&#xD;
&#xD;
          7. Hemoglobin A1c is 10 or less;&#xD;
&#xD;
          8. Normotensive with or without medications;&#xD;
&#xD;
          9. Without retinal capillary dropout or macular edema;&#xD;
&#xD;
         10. Blood homocysteine &gt; 9.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        The subjects will be ineligible for entry into the study if s/he:&#xD;
&#xD;
          1. Has an active ocular disease;&#xD;
&#xD;
          2. Has had surgery or an eye injury within 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianhua Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bascom Palmer Eye Institute, University of Miami, Miami, FL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianhua Wang, MD, PhD</last_name>
    <phone>3054825010</phone>
    <email>jwang3@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Wang, MD, PHD</last_name>
      <phone>305-482-5010</phone>
      <email>jwang3@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jianhua Wang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Jianhua (Jay) Wang, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

